Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors	Advanced Solid Tumor	Recruiting	Phase 1 / Phase 2	2026-08-17		NCT06635785

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
OncoC4, Inc.	8

21 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
AdventHealth Cancer Institute	Orlando	United States	11
Dana-Farber Cancer Institute	Boston	United States	626
Duke University Medical Center - Duke Cancer Center	Durham	United States	7
Henry Ford Health	Detroit	United States	75
Highlands Oncology Group	Springdale	United States	62
MD Anderson Cancer Center	Houston	United States	589
MedStar Georgetown University Hospital	Washington D.C.	United States	204
Memorial Healthcare System	Hollywood	United States	31
Northwestern University	Chicago	United States	727
Norton Cancer Center	Louisville	United States	2
Novant Health Cancer Institute	Winston-Salem	United States	4
Ocala Oncology Center PL DBA Florida Cancer Affiliates	Ocala	United States	1
Prisma Health	Greenville	United States	24
The Ohio State University James Cancer Center	Columbus	United States	2
The Tisch Cancer Institute, Mount Sinai Medical Center	New York	United States	1
University of Alabama at Birmingham	Birmingham	United States	193
University of Florida UF Health Cancer Center	Gainesville	United States	1
University of Michigan Rogel Cancer Center	Ann Arbor	United States	186
University of North Carolina at Chapel Hill Cancer Center	Chapel Hill	United States	1
University of Texas Health San Antonio Mays Cancer Center	San Antonio	United States	1
University of Utah Huntsman Cancer Institute	Salt Lake City	United States	15

Clinical trials